Tirzepatide in type 1 diabetes: cardiometabolic effects (TIRTLE)

Cardiovascular disease and its risk factors are prominent issues in type 1 diabetes. There is a need to identify treatments that can address weight, blood sugar management and heart disease risk factors in type 1 diabetes. Tirzepatide is a medication usually used in type 2 diabetes. Whether tirzepatide improves health in type 1 diabetes has not been studied before. The TIRTLE study is a clinical trial studying the effect of tirzepatide on weight and metabolism in adults with type 1 diabetes.

Treatment

The study medication in this trial is given by injection into the skin once a week for 12 weeks. For every 2 participants, 1 will receive the study medication, and 1 will receive placebo. The allocation of medication is done randomly.

Study visits

Volunteers briefly visit the Garvan Institute of Medical Research, Darlinghurst, Sydney, NSW, every week to receive their treatment dose. There are also:

– 2 visits before treatment: visit 1 – 1.5 hours with option for online attendance, visit 2 – up to 3 hours at the Garvan Institute

– 2 visits at the end of treatment, after 12 weeks: visit 3 – 1.5 hours with option for online attendance, visit 4 – up to 3 hours at the Garvan Institute

– In between, volunteers briefly visit the Garvan Institute every week to receive their treatment dose.

Benefits of participation

In addition to improving knowledge about weight management and metabolic health in type 1 diabetes, test results such as body composition measurements will be shared with you.

There is no cost to participate in the study.

Contact

Email: TIRTLE@garvan.org.au

Phone : 0491 731 769